Reviva to present brilaroxazine topline data for long-term ole portion of recover study in schizophrenia at 2025 sirs congress

Cupertino, calif., march 30, 2025 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the phase 3 recover study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 congress of the schizophrenia international research society (sirs) taking place march 29 to april 2, 2025 in chicago, illinois, u.s.
RVPH Ratings Summary
RVPH Quant Ranking